- Home
- WF vs ROIV Comparison
WF vs ROIV Comparison
Compare WF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WF
- ROIV
- Stock Information
- Founded
- WF 1899
- ROIV 2014
- Country
- WF South Korea
- ROIV United Kingdom
- Employees
- WF N/A
- ROIV N/A
- Industry
- WF Commercial Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- WF Finance
- ROIV Health Care
- Exchange
- WF Nasdaq
- ROIV Nasdaq
- Market Cap
- WF 8.9B
- ROIV 8.8B
- IPO Year
- WF N/A
- ROIV N/A
- Fundamental
- Price
- WF $32.87
- ROIV $12.01
- Analyst Decision
- WF
- ROIV Strong Buy
- Analyst Count
- WF 0
- ROIV 8
- Target Price
- WF N/A
- ROIV $17.93
- AVG Volume (30 Days)
- WF 64.4K
- ROIV 4.6M
- Earning Date
- WF 11-14-2024
- ROIV 02-11-2025
- Dividend Yield
- WF 11.39%
- ROIV N/A
- EPS Growth
- WF N/A
- ROIV N/A
- EPS
- WF 2.64
- ROIV 5.89
- Revenue
- WF $7,567,454,676.00
- ROIV $129,128,999.00
- Revenue This Year
- WF N/A
- ROIV $15.98
- Revenue Next Year
- WF $1.69
- ROIV N/A
- P/E Ratio
- WF $4.02
- ROIV $2.06
- Revenue Growth
- WF N/A
- ROIV 145.68
- 52 Week Low
- WF $27.60
- ROIV $9.69
- 52 Week High
- WF $38.05
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- WF 35.04
- ROIV 52.23
- Support Level
- WF $31.82
- ROIV $11.72
- Resistance Level
- WF $33.28
- ROIV $12.43
- Average True Range (ATR)
- WF 0.47
- ROIV 0.27
- MACD
- WF -0.24
- ROIV -0.03
- Stochastic Oscillator
- WF 15.00
- ROIV 37.10
About WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holdings company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. Its operating segments include Banking, Credit card, capital, Investment banking, and others.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.